All In Biotech

Drug Trial Radar · NCT05952986

A Study to Evaluate the Safety and Bridging PK Profile of FB825 for Single Subcutaneous Administration in Healthy Adults

A Randomized, Placebo-Controlled, Double-Blind, Phase I Study to Evaluate the Safety and Bridging Pharmacokinetics Profile of FB825 for Single Subcutaneous Administration in Healthy Adults

Last checked: Nov 19, 2026Latest source record: Jan 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

22

Actual

Start

May 3, 2023

Primary completion

Mar 26, 2024

Study completion Mar 26, 2024

Sponsor

Lead sponsor
Oneness Biotech Co., Ltd.Industry
Sponsor type
Industry
First posted
Jul 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, placebo-controlled, and double-blind study to evaluate the safety and bridging PK profile of FB825 for single SC administration in healthy adults.

Conditions

  • Atopic Dermatitis

Interventions

  • FB825 or Placebo in subcutaneous routeDrug

    FB825 or placebo solution for SC injection

  • FB825 in intravenous routeDrug

    FB825 solution for IV infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse eventTime frame: 24 months
  2. AUC0-infTime frame: 19 months
  3. AUC0-tTime frame: 19 months
  4. CmaxTime frame: 19 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Phase I center

    Anaheim, California

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.